Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

September

28

ATEC Provides Business Update

ATEC to showcase its comprehensive portfolio of innovative spine solutions and partner with renowned...

22

DVI and Neurolens Collaborate to Increase Prism Specificity

At least two out of three patients experience the symptoms of eye misalignment. Coppell,...

21

electroCore Announces Peter Cuneo as Board Chairman

ROCKAWAY, NJ, Sept. 20, 2021 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today...

15

Neurolens Names Pierre Bertrand Chief Executive Officer

Founder Davis Corley will transition to executive chairman of the board of directors Coppell,...

15

electroCore Announces New Patent Expanding Claims Related to Delivery of Non-Invasive Vagus Nerve Stimulation Therapy Using Mobile Devices

ECOR’s eighth US patent allows patients to self-treat medical conditions such as migraine headache...

15

ATEC to Feature Comprehensive Procedural Solutions at NASS 2021

Clinical benefits of Prone TransPsoas (PTP)™approach and EOS imaging technology to be showcased in...

14

electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Paroxysmal Hemicrania and Hemicrania Continua

These rare forms of trigeminal autonomic cephalalgias are typically debilitating and difficult to treat...

7

TriSalus Life Sciences Announces First Patient Enrolled in PERIO-01 Clinical Trial to Evaluate Delivery of SD-101 via Pressure-Enabled Drug Delivery in Uveal Melanoma Liver Metastases

Study to evaluate the delivery of SD-101, an investigational TLR9 agonist, in combination with...

24

electroCore Announces New Reseller Agreement with Red One Medical Devices, LLC

Partnership will expand gammaCore federal market availability ROCKAWAY, NJ, Aug. 24, 2021 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq:...

10

Study of Non-Invasive Vagus Nerve Stimulation (nVNS) Shows Improvement in PTSD Symptoms and Decreased Inflammatory Response to Stress

Peer-reviewed manuscript reports results of study conducted at Georgia Tech and Emory, funded in...

9

Exagen Inc. Reports Second Quarter 2021 Results

Quarterly Records: Total Revenue, AVISE® CTD Revenue and Volumes, Ordering Healthcare Providers and Adopters...

5

electroCore Announces Second Quarter 2021 Financial Results

Second quarter 2021 net sales of $1.3 million, increased 69% over second quarter 2020...

Recent developments

News

September

28

ATEC Provides Business Update

September

22

DVI and Neurolens Collaborate to Increase Prism Specificity

September

21

electroCore Announces Peter Cuneo as Board Chairman

September

15

Neurolens Names Pierre Bertrand Chief Executive Officer

September

15

electroCore Announces New Patent Expanding Claims Related to Delivery of Non-Invasive Vagus Nerve Stimulation Therapy Using Mobile Devices

September

15

ATEC to Feature Comprehensive Procedural Solutions at NASS 2021

September

14

electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Paroxysmal Hemicrania and Hemicrania Continua

September

7

TriSalus Life Sciences Announces First Patient Enrolled in PERIO-01 Clinical Trial to Evaluate Delivery of SD-101 via Pressure-Enabled Drug Delivery in Uveal Melanoma Liver Metastases

August

24

electroCore Announces New Reseller Agreement with Red One Medical Devices, LLC

August

10

Study of Non-Invasive Vagus Nerve Stimulation (nVNS) Shows Improvement in PTSD Symptoms and Decreased Inflammatory Response to Stress

August

9

Exagen Inc. Reports Second Quarter 2021 Results

August

5

electroCore Announces Second Quarter 2021 Financial Results